Saint Sebastien sur Loire, France

Aurore Morello

USPTO Granted Patents = 2 

 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Aurore Morello - Innovator in Cancer Treatment

Introduction

Aurore Morello is a prominent inventor based in Saint Sebastien sur Loire, France. With a focus on groundbreaking innovations in cancer treatment, Morello holds a significant patent that showcases her contributions to the field of immunotherapy.

Latest Patents

One of Aurore Morello's notable patents is titled "Humanized anti-human-PD-1 antibody and its use in cancer treatment." This invention details humanized anti-PD-1 antibodies, nucleic acids encoding such antibodies, and their applications in enhancing immune responses through T cell activation. This innovative approach aims to treat diseases, including cancer and certain infectious diseases, representing a significant advancement in therapeutic interventions.

Career Highlights

Aurore Morello is currently affiliated with Ose Immunotherapeutics, a company dedicated to developing novel immunotherapy solutions. Her work in this dynamic and rapidly evolving field highlights her commitment to creating effective treatments that harness the body's immune system to combat disease.

Collaborations

Throughout her career, Morello has collaborated with esteemed colleagues such as Nicolas Poirier and Caroline Mary. Their teamwork exemplifies the collaborative spirit of the scientific community, driving forward the frontiers of immunotherapy and making strides towards more effective cancer treatments.

Conclusion

Aurore Morello's innovative work and patent in the realm of cancer treatment demonstrate her significant contributions to medical science. Her collaboration with dedicated professionals and her role at Ose Immunotherapeutics underscore her impact on improving immune therapies for the benefit of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…